SlideShare a Scribd company logo
1 of 10
Download to read offline
CMP 4521.90
Target Price 5110.00
ISIN: INE322A01010
May 30th
, 2015
GILLETTE INDIA LIMITED
Result Update (PARENT BASIS): Q3 FY15
BUYBUYBUYBUY
Stock Data
Sector FMCG
BSE Code 507815
Face Value / Div. Per Share 10.00
52wk. High / Low (Rs.) 4999.00/1925.05
Volume (2wk. Avg ) 890
Market Cap ( Rs in mn ) 147368.72
Annual Estimated Results (A*: Actual / E*: Estimated)
Years FY14A FY15E FY16E
Net Sales 17497.90 19613.20 21574.52
EBITDA 1140.00 2242.89 2587.63
Net Profit 514.20 1167.40 1370.36
EPS 15.78 35.82 42.05
P/E 286.60 126.24 107.54
Shareholding Pattern (%)
1 Year Comparative Graph
GILLETTE INDIA LTD BSE SENSEX
Highlights
Gillette India Limited offers personal grooming, oral
care, and portable power products in India and
internationally.
The company’s Net Sales was at Rs. 4941.40 million
for the Mar quarter of FY15 compared to Rs. 4555.00
million in corresponding quarter of previous year,
registered a robust growth of 8.48% y-o-y.
In Q3 FY15, PAT or Net Profit grew by 262.74% y-o-y
and stood at Rs. 307.60 million compared to Rs.
84.80 million in Q3 FY14.
During the March quarter, Profit before interest,
depreciation and tax is Rs. 550.70 million as against
Rs. 224.30 million in the corresponding period of the
previous year.
In Q3 FY15, Profit before Tax (PBT) ramps up by
213.43% to Rs. 438.80 million from Rs. 140.00
million in Q3 FY14.
For Q3 FY15, Sales in grooming portfolio were up by
9% to Rs. 3555.10 million from Rs. 3247.00 million
for the corresponding quarter of previous year.
In Q3 FY15, Oral Care and Portable Power business
delivered sales growth of 6% & 4% of Rs. 1168.90
million and Rs. 217.40 million respectively compared
to prior period of previous year.
Net profit grew by 146.11% to Rs. 853.00 million for
the end of 9M FY15 from Rs 346.60 million for the
end of 9M FY14.
Net Sales and PAT of the company are expected to
grow at a CAGR of 15% & 16% over 2013 to 2016E
respectively.
PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND
Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
Gillette India Ltd 4521.90 147368.72 15.78 286.60 22.90 150.00
Colgate Palmolive Ltd 2000.55 272060.40 41.10 48.68 23.48 2400.00
Procter & Gamble Hygiene & Health Care LTD 6366.25 206653.20 101.34 62.82 20.61 275.00
Godrej Consumer Products Ltd 1074.00 365640.00 19.22 55.88 9.94 550.00
ANALYSIS & RECOMMENDATION - ‘BUY’
Gillette India Limited reported 8.74% rise in total Income (including other income) in its 3rd quarter March
results. Total Income stood at Rs. 5006.40 million compared to Rs. 4603.80 million in corresponding quarter of
previous year. Growth in sales was seen across all business segments – Grooming (9%), Oral Care (6%) &
Portable Power (4%). The company reported Operating Profit or EBDITA of Rs. 550.70 million in Q3 FY15
compared to Rs. 224.30 million in Q3 FY14. In the same Mar quarter of FY15, Profit after Tax Jumps to 262.74%
y-o-y of Rs. 307.60 million compared to Rs. 84.80 million in the same period previous year. Net profit of the
company has shown a three digit growth performance behind productivity driven cost .savings and operational
excellence. For the nine months ended of FY15, the company registered a growth of 12.80% in Net sales to Rs.
14325.90 million from Rs. 12700.70 million for the nine months ended of FY14. Net profit grew by 146.11% to
Rs. 853.00 million for the end of 9M FY15 from Rs 346.60 million for the end of 9M FY14.Gillette, Oral-B &
Duracell have strong brand recall & command significant market share in their respective categories. Thus, we
recommend ‘BUY’ for ‘Gillette India Ltd’ with a target price of Rs. 5110.00 for medium term investment.
QUARTERLY HIGHLIGHTS (PARENT BASIS)
Results updates- Q3 FY15,
Gillette India Limited Is one of India’s well known FMCG companies that has its portfolio Gillette Mach 3 Torbo,
Oral-B and Duracell is a World leading brands. Reported its financial result for the quarter ended 31st Mar, 2015.
The company’s Net profit Jumps to Rs. 307.60 million against Rs. 84.80 million in the corresponding quarter of
previous year, an increase of 262.74% y-o-y. Net Sales of Rs. 4941.40 million for the March quarter of FY15
compared to Rs. 4555.00 million for the corresponding quarter of previous year. Driven by the company’s focus
on innovation, net sales increased a growth of 8.48% y-o-y with a robust growth across all segments including
Grooming, Oral Care and portable power. Profit before interest, depreciation and tax is Rs. 550.70 million, an
increase of 145.52% y-o-y as against Rs. 224.30 million in the corresponding period of the previous year. For the
March quarter, Reported earnings per share of the company stood at Rs. 9.44 a share, registering 262.74%
increase over previous year period.
Rs. In Mn Mar-15 Mar-14 % Change
Net Sales 4941.40 4555.00 8.48
PAT 307.60 84.80 262.74
EPS 9.44 2.60 262.74
EBITDA 550.70 224.30 145.52
Break Up of Expenditure
(Rs. In Million) Q3 FY15 Q3 FY14 CHNG %
Cost of raw & packing materials consumed 1057.50 1097.60 -4%
Purchase of stock-in-trade 1022.10 1138.60 -10%
Employees Benefit Expenses 312.80 176.40 77%
Depreciation and amortization 105.60 79.80 32%
Advertising & sales promotion expenses 1167.10 1238.40 -6%
Other Expenditure 734.60 763.70 -4%
Segment Revenue
Rs. In Mn Q3 FY15 Q3 FY14 CHNG %
Grooming 3555.10 3247.00 9%
Portable power 217.40 208.30 4%
Oral Care 1168.90 1099.70 6%
COMPANY PROFILE
Gillette India Limited offers personal grooming, oral care, and portable power products in India and
internationally. It provides personal grooming products, such as blades, razors, and toiletries under the Gillette
brand; oral care products, including tooth brushes and other oral care products under the Oral-B brand; and
portable power products comprising batteries under the Duracell brand. The company, formerly known as
Indian Shaving Products Limited, was incorporated in 1985 and is based in Mumbai, India. Gillette India Limited
is a subsidiary of Procter & Gamble India Holdings B.V.
P&G entered India in 1988, and now serves over 650 mm consumers across India. The company presence in
household, beauty, grooming and health care segments. Acquired Gillette India in 2005 – Fully integrated with
P&G’s strategies & values P&G operates two listed entities (Gillette India Limited and Procter & Gamble Hygiene
& Health Care Limited) & one wholly owned subsidiary (Procter & Gamble Home Products Limited) in India.
Products
• Personal grooming- blades & razors
• Oral care
• Portable power
Financial Statements & Estimations (PARENT BASIS) (A*- Actual, E* -Estimations & Rs. In Millions)
Balance sheet as at June 30, 2013A- 2016E
2013A 2014A 2015E 2016E
EQUITY AND LIABILITIES:
Shareholders’ Funds:
Share Capital 325.90 325.90 325.90 325.90
Reserves and Surplus 6166.40 6108.70 6719.57 7324.33
1) Sub Total - Net worth 6492.30 6434.60 7045.47 7650.23
Non-Current Liabilities:
Deferred Tax Liabilities [Net] 64.00 23.50 10.58 5.82
Other Long Term Liabilities 0.20 0.20 0.20 0.20
Long Term Provisions 15.00 21.60 24.62 27.09
2) Sub Total - Non Current Liabilities 79.20 45.30 35.40 33.10
Current Liabilities:
Trade Payables 2236.70 2560.50 2893.37 3182.70
Other Current Liabilities 653.40 515.80 533.34 544.00
Short Term Provisions 928.70 984.40 610.33 384.51
3) Sub Total - Current Liabilities 3818.80 4060.70 4037.03 4111.21
Total Liabilities (1+2+3) 10390.30 10540.60 11117.90 11794.55
ASSETS:
Non-Current Assets:
Fixed Assets:
Tangible Assets 1702.10 1726.30 1771.18 1799.52
Capital work-in-progress 297.80 608.40 797.00 940.46
a) Sub Total - Fixed Assets: 1999.90 2334.70 2568.19 2739.99
b) Long Term Loans and Advances 1014.80 1237.90 1435.96 1608.28
4) Sub Total - Non-Current Assets 3014.70 3572.60 4004.15 4348.27
Current Assets:
Inventories 2397.30 2305.50 2503.77 2618.95
Trade Receivables 927.00 922.60 929.98 948.58
Cash and Bank Balances 1668.20 1696.10 908.23 935.48
Short Term Loans and Advances 2183.10 1975.80 2696.97 2862.49
Other Current Assets 200.00 68.00 74.80 80.78
5) Sub Total - Current Assets 7375.60 6968.00 7113.75 7446.28
Total Assets (4+5) 10390.30 10540.60 11117.90 11794.55
Annual Profit & Loss Statement for the period of 2013 to 2016E
Value(Rs.in.mn) FY13A FY14A FY15E FY16E
Description 12m 12m 12m 12m
Net Sales 14377.20 17497.90 19613.20 21574.52
Other Income 365.50 316.20 361.40 451.75
Total Income 14742.70 17814.10 19974.60 22026.27
Expenditure -13046.80 -16674.10 -17731.70 -19438.64
Operating Profit 1695.90 1140.00 2242.89 2587.63
Interest -0.20 -3.60 -46.98 -60.13
Gross profit 1695.70 1136.40 2195.92 2527.50
Depreciation -313.20 -329.80 -416.79 -466.80
Profit Before Tax 1382.50 806.60 1779.13 2060.69
Tax -510.90 -292.40 -611.73 -690.33
Net Profit 871.60 514.20 1167.40 1370.36
Equity capital 325.90 325.90 325.90 325.90
Reserves 6166.40 6108.70 6780.66 7324.33
Face value 10.00 10.00 10.00 10.00
EPS 26.74 15.78 35.82 42.05
Quarterly Profit & Loss Statement for the period of 30th Sept 2014 to 30th June, 2015E
Value(Rs.in.mn) 30-Sep-14 31-Dec-14 31-Mar-15 30-Jun-15E
Description 3m 3m 3m 3m
Net Sales 4399.80 4984.70 4941.40 5287.30
Other income 156.60 56.60 65.00 83.20
Total Income 4556.40 5041.30 5006.40 5370.50
Expenditure -4172.90 -4318.10 -4455.70 -4785.00
Operating profit 383.50 723.20 550.70 585.49
Interest -24.00 -13.40 -6.30 -3.28
Gross profit 359.50 709.80 544.40 582.22
Depreciation -85.00 -118.90 -105.60 -107.29
Profit Before Tax 274.50 590.90 438.80 474.93
Tax -97.70 -222.30 -131.20 -160.53
Net Profit 176.80 368.60 307.60 314.40
Equity capital 325.90 325.90 325.90 325.90
Face value 10.00 10.00 10.00 10.00
EPS 5.42 11.31 9.44 9.65
Ratio Analysis
Particulars FY13A FY14A FY15E FY16E
EPS (Rs.) 26.74 15.78 35.82 42.05
EBITDA Margin (%) 11.80% 6.52% 11.44% 11.99%
PBT Margin (%) 9.62% 4.61% 9.07% 9.55%
PAT Margin (%) 6.06% 2.94% 5.95% 6.35%
P/E Ratio (x) 169.08 286.60 126.24 107.54
ROE (%) 13.43% 7.99% 16.57% 17.91%
ROCE (%) 30.95% 22.84% 37.75% 39.93%
EV/EBITDA (x) 85.91 127.78 65.30 56.59
Book Value (Rs.) 199.21 197.44 216.19 234.74
P/BV 22.70 22.90 20.92 19.26
Charts
Outlook and Conclusion
At the current market price of Rs.4521.90, the stock P/E ratio is at 126.24 x FY15E and 107.54 x FY16E
respectively.
Earning per share (EPS) of the company for the earnings for FY15E and FY16E is seen at Rs.35.82 and
Rs.42.05 respectively.
Net Sales and PAT of the company are expected to grow at a CAGR of 16% & 15% over 2013 to 2016E
respectively.
On the basis of EV/EBITDA, the stock trades 65.30 x for FY15E and 56.59 x for FY16E.
Price to Book Value of the stock is expected to be at 20.92 x and 19.26 x respectively for FY15E and FY16E.
We recommend ‘BUY’ in this particular scrip with a target price of Rs.5110.00 for Medium to Long term
investment.
Industry Overview
The Indian FMCG sector is around $15 Billion and continues to grow at a healthy pace, though it has slowed
down versus the historical growth rate. The long term prospects remain bright. There is significant opportunity
to grow penetration, trial and consumption. Has strong Indian companies and major multinationals operating in
this area offering a wide array of products to the Indian consumer.
MALE GROOMING — BLADES & RAZOR
Blades & Razor sector is a big category and represents a sizable growth opportunity for this Company. The
Blades & Razors market size is estimated at over Rs. 20000.00 mn. The strong portfolio and outstanding equity of
Gillette has helped us deliver another year of robust double digit growth and record shares.
ORAL CARE
The Oral Care category which is over Rs.100000.00 mn presents significant opportunities as well as challenges in
India. The Oral Care business delivered over 30% topline growth versus last year driven by product innovations
including launch of Oral-B toothpaste and focus on brand fundamentals. The Company’s entry into the
toothpastemarket is delivering results in line with expectations but will require significant investment.
PORTABLE POWER
The growing usage in the high and mid drain devices like toys and cameras and increased purchasing power in
India indicate a good potential in the coming years for alkaline batteries and thus for Duracell. Sales in this
segment were up more than 20% versus last year.
Outlook, Risks and Opportunities
The Indian economy presents significant opportunity with a growing population, category whitespace and rising
incomes. We do expect growth rate in the categories we compete to be around high single digits. However, high
inflation, supply bottlenecks and intense competition present significant near term challenges. The Company
endeavors to overcome these risks and to sustain and improve its market position behind superior innovation,
strategic pricing, effective communication and by focusing relentlessly on productivity.
Conclusion
While the rural market certainly offers a big attraction to marketers, it would be naïve to think that any company
can enter the market without facing any problems and walk away with a sizable share. Distribution is the most
important variable in the marketing plans of most consumer goods manufacturers, because managing such a
massive sales and distribution network is in itself a huge task.
This sector will continue to see growth as it depends on an ever-increasing internal market for consumption, and
demand for these goods remains more or less constant, irrespective of recession or inflation. Hence this sector
will grow, though it may not be a smooth growth path, due to the present world-wide economic slowdown, rising
inflation and fall of the rupee. This sector will see good growth in the long run and hiring will continue to remain
robust.
The Indian economy is showing positive signals of regaining growth momentum, especially in core areas of
Manufacturing and Infrastructure. However, the weaker than expected monsoon is an area of worry and could
impact growth as well as consumption. The recent stability in the rupee is welcome news as it enables the
economic recovery.
Disclaimer:
This document is prepared by our research analysts and it does not constitute an offer or solicitation for the
purchase or sale of any financial instrument or as an official confirmation of any transaction. The information
contained herein is from publicly available data or other sources believed to be reliable but we do not represent that
it is accurate or complete and it should not be relied on as such. Firstcall Research or any of its affiliates shall not be
in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this report. Firstcall Research and/ or its affiliates and/or employees will not be liable for
the recipients’ investment decision based on this document.
Firstcall India Equity Research: Email – info@firstobjectindia.com
C.V.S.L.Kameswari Pharma & Diversified
U. Janaki Rao Capital Goods
B. Anil Kumar Auto, IT & FMCG
M. Vinayak Rao Diversified
G. Amarender Diversified
Firstcall Research Provides
Industry Research on all the Sectors and Equity Research on Major Companies
forming part of Listed and Unlisted Segments
For Further Details Contact:
Tel.: 022-2527 2510/2527 6077 / 25276089 Telefax: 022-25276089
040-20000235 /20000233
E-mail: info@firstobjectindia.com
www.firstcallresearch.com

More Related Content

What's hot

Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'IndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...IndiaNotes.com
 
Q4FY15 results: Revenue up 16.73%; Buy for a target of 1950
Q4FY15 results: Revenue up 16.73%; Buy for a target of 1950Q4FY15 results: Revenue up 16.73%; Buy for a target of 1950
Q4FY15 results: Revenue up 16.73%; Buy for a target of 1950IndiaNotes.com
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtIndiaNotes.com
 
Orbit Exports Q4FY15: Growth story to continue in coming quarters also
Orbit Exports Q4FY15: Growth story to continue in coming quarters alsoOrbit Exports Q4FY15: Growth story to continue in coming quarters also
Orbit Exports Q4FY15: Growth story to continue in coming quarters alsoIndiaNotes.com
 
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'IndiaNotes.com
 
Indian coding and marking sector reaching maturity, Buy Control Print
Indian coding and marking sector reaching maturity, Buy Control PrintIndian coding and marking sector reaching maturity, Buy Control Print
Indian coding and marking sector reaching maturity, Buy Control PrintIndiaNotes.com
 
http://www.indianotes.com/uploads/article_pdf/2015/smc_SunPharma_04Jun15.pdf
http://www.indianotes.com/uploads/article_pdf/2015/smc_SunPharma_04Jun15.pdfhttp://www.indianotes.com/uploads/article_pdf/2015/smc_SunPharma_04Jun15.pdf
http://www.indianotes.com/uploads/article_pdf/2015/smc_SunPharma_04Jun15.pdfIndiaNotes.com
 
Kitex: ICRA upgrades long and short-term ratings to AA minus and A one Plus; Buy
Kitex: ICRA upgrades long and short-term ratings to AA minus and A one Plus; BuyKitex: ICRA upgrades long and short-term ratings to AA minus and A one Plus; Buy
Kitex: ICRA upgrades long and short-term ratings to AA minus and A one Plus; BuyIndiaNotes.com
 
Saral Gyan Hidden Gem - Sept 2015
Saral Gyan Hidden Gem - Sept 2015Saral Gyan Hidden Gem - Sept 2015
Saral Gyan Hidden Gem - Sept 2015SaralGyanTeam
 
Will rapid urbanisation propel growth in Hitech Plast?
Will rapid urbanisation propel growth in Hitech Plast?Will rapid urbanisation propel growth in Hitech Plast?
Will rapid urbanisation propel growth in Hitech Plast?IndiaNotes.com
 
Firstcall recommends a textile stock for the mid- to long-term
Firstcall recommends a textile stock for the mid- to long-termFirstcall recommends a textile stock for the mid- to long-term
Firstcall recommends a textile stock for the mid- to long-termIndiaNotes.com
 
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'IndiaNotes.com
 
Firstcall recommend PI Industries after Q4FY15 net profits rise 33.47% y/y
Firstcall recommend PI Industries after Q4FY15 net profits rise 33.47% y/yFirstcall recommend PI Industries after Q4FY15 net profits rise 33.47% y/y
Firstcall recommend PI Industries after Q4FY15 net profits rise 33.47% y/yIndiaNotes.com
 
Excel Crop Care: Net profit ramps up by 214% in FY14, buy
Excel Crop Care: Net profit ramps up by 214% in FY14, buyExcel Crop Care: Net profit ramps up by 214% in FY14, buy
Excel Crop Care: Net profit ramps up by 214% in FY14, buyIndiaNotes.com
 
Buy Bharat Rasayan, Indian agrochemical sector pegged at $7.5b by FY19
Buy Bharat Rasayan, Indian agrochemical sector pegged at $7.5b by FY19Buy Bharat Rasayan, Indian agrochemical sector pegged at $7.5b by FY19
Buy Bharat Rasayan, Indian agrochemical sector pegged at $7.5b by FY19IndiaNotes.com
 
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/yFirstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/yIndiaNotes.com
 
Firstcall metroglobal limited_13jul15
Firstcall metroglobal limited_13jul15Firstcall metroglobal limited_13jul15
Firstcall metroglobal limited_13jul15IndiaNotes.com
 
Sitara chemical industry........hj
Sitara chemical industry........hjSitara chemical industry........hj
Sitara chemical industry........hjArfan Afzal
 

What's hot (19)

Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Q4FY15 results: Revenue up 16.73%; Buy for a target of 1950
Q4FY15 results: Revenue up 16.73%; Buy for a target of 1950Q4FY15 results: Revenue up 16.73%; Buy for a target of 1950
Q4FY15 results: Revenue up 16.73%; Buy for a target of 1950
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Orbit Exports Q4FY15: Growth story to continue in coming quarters also
Orbit Exports Q4FY15: Growth story to continue in coming quarters alsoOrbit Exports Q4FY15: Growth story to continue in coming quarters also
Orbit Exports Q4FY15: Growth story to continue in coming quarters also
 
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
Multibase India's FY15 net profit up 42% y/y, Firstcall recommend 'Buy'
 
Indian coding and marking sector reaching maturity, Buy Control Print
Indian coding and marking sector reaching maturity, Buy Control PrintIndian coding and marking sector reaching maturity, Buy Control Print
Indian coding and marking sector reaching maturity, Buy Control Print
 
http://www.indianotes.com/uploads/article_pdf/2015/smc_SunPharma_04Jun15.pdf
http://www.indianotes.com/uploads/article_pdf/2015/smc_SunPharma_04Jun15.pdfhttp://www.indianotes.com/uploads/article_pdf/2015/smc_SunPharma_04Jun15.pdf
http://www.indianotes.com/uploads/article_pdf/2015/smc_SunPharma_04Jun15.pdf
 
Kitex: ICRA upgrades long and short-term ratings to AA minus and A one Plus; Buy
Kitex: ICRA upgrades long and short-term ratings to AA minus and A one Plus; BuyKitex: ICRA upgrades long and short-term ratings to AA minus and A one Plus; Buy
Kitex: ICRA upgrades long and short-term ratings to AA minus and A one Plus; Buy
 
Saral Gyan Hidden Gem - Sept 2015
Saral Gyan Hidden Gem - Sept 2015Saral Gyan Hidden Gem - Sept 2015
Saral Gyan Hidden Gem - Sept 2015
 
Will rapid urbanisation propel growth in Hitech Plast?
Will rapid urbanisation propel growth in Hitech Plast?Will rapid urbanisation propel growth in Hitech Plast?
Will rapid urbanisation propel growth in Hitech Plast?
 
Firstcall recommends a textile stock for the mid- to long-term
Firstcall recommends a textile stock for the mid- to long-termFirstcall recommends a textile stock for the mid- to long-term
Firstcall recommends a textile stock for the mid- to long-term
 
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
 
Firstcall recommend PI Industries after Q4FY15 net profits rise 33.47% y/y
Firstcall recommend PI Industries after Q4FY15 net profits rise 33.47% y/yFirstcall recommend PI Industries after Q4FY15 net profits rise 33.47% y/y
Firstcall recommend PI Industries after Q4FY15 net profits rise 33.47% y/y
 
Excel Crop Care: Net profit ramps up by 214% in FY14, buy
Excel Crop Care: Net profit ramps up by 214% in FY14, buyExcel Crop Care: Net profit ramps up by 214% in FY14, buy
Excel Crop Care: Net profit ramps up by 214% in FY14, buy
 
Buy Bharat Rasayan, Indian agrochemical sector pegged at $7.5b by FY19
Buy Bharat Rasayan, Indian agrochemical sector pegged at $7.5b by FY19Buy Bharat Rasayan, Indian agrochemical sector pegged at $7.5b by FY19
Buy Bharat Rasayan, Indian agrochemical sector pegged at $7.5b by FY19
 
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/yFirstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
 
Firstcall metroglobal limited_13jul15
Firstcall metroglobal limited_13jul15Firstcall metroglobal limited_13jul15
Firstcall metroglobal limited_13jul15
 
Sitara chemical industry........hj
Sitara chemical industry........hjSitara chemical industry........hj
Sitara chemical industry........hj
 

Similar to Firstcall gillette 01jun15[1]

GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
Sanofi India: Q2CY14 net rises 12.30%, maintain buy
 Sanofi India: Q2CY14 net rises 12.30%, maintain buy Sanofi India: Q2CY14 net rises 12.30%, maintain buy
Sanofi India: Q2CY14 net rises 12.30%, maintain buyIndiaNotes.com
 
Firstcall atul 7may15[1]
Firstcall atul 7may15[1]Firstcall atul 7may15[1]
Firstcall atul 7may15[1]IndiaNotes.com
 
Divi's Lab Q4FY15: Net profit up 18.57% y/y to INR2,289.10m, Firstcall recomm...
Divi's Lab Q4FY15: Net profit up 18.57% y/y to INR2,289.10m, Firstcall recomm...Divi's Lab Q4FY15: Net profit up 18.57% y/y to INR2,289.10m, Firstcall recomm...
Divi's Lab Q4FY15: Net profit up 18.57% y/y to INR2,289.10m, Firstcall recomm...IndiaNotes.com
 
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyAgro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyIndiaNotes.com
 
Cadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India Equity
Cadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India EquityCadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India Equity
Cadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India EquityIndiaNotes.com
 
Firstcall recommends an ethnic Indian foods scrip
Firstcall recommends an ethnic Indian foods scripFirstcall recommends an ethnic Indian foods scrip
Firstcall recommends an ethnic Indian foods scripIndiaNotes.com
 
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 yearsBuy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 yearsIndiaNotes.com
 
Tata Sponge: Q1 Net grows a whopping 145.45%, buy
Tata Sponge: Q1 Net grows a whopping 145.45%, buyTata Sponge: Q1 Net grows a whopping 145.45%, buy
Tata Sponge: Q1 Net grows a whopping 145.45%, buyIndiaNotes.com
 
Firstcall recommend GHCL on 31.45% y/y rise in Q4FY15 net profit
Firstcall recommend GHCL on 31.45% y/y rise in Q4FY15 net profitFirstcall recommend GHCL on 31.45% y/y rise in Q4FY15 net profit
Firstcall recommend GHCL on 31.45% y/y rise in Q4FY15 net profitIndiaNotes.com
 
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buyWelspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buyIndiaNotes.com
 
Fce tvs motors_28_jul15
Fce tvs motors_28_jul15Fce tvs motors_28_jul15
Fce tvs motors_28_jul15IndiaNotes.com
 
SKF India's net profit jumps to Rs512.40 mn during Q1CY15; Buy
SKF India's net profit jumps to Rs512.40 mn during Q1CY15; BuySKF India's net profit jumps to Rs512.40 mn during Q1CY15; Buy
SKF India's net profit jumps to Rs512.40 mn during Q1CY15; BuyIndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyIndiaNotes.com
 
Firstcall sandesh 10_apr15[1]
Firstcall sandesh 10_apr15[1]Firstcall sandesh 10_apr15[1]
Firstcall sandesh 10_apr15[1]IndiaNotes.com
 
Sun TV can be bought for target of Rs430 for the mid- to long-term according ...
Sun TV can be bought for target of Rs430 for the mid- to long-term according ...Sun TV can be bought for target of Rs430 for the mid- to long-term according ...
Sun TV can be bought for target of Rs430 for the mid- to long-term according ...IndiaNotes.com
 
Go long on Simmonds Marshall for the mid- to long-term
Go long on Simmonds Marshall for the mid- to long-termGo long on Simmonds Marshall for the mid- to long-term
Go long on Simmonds Marshall for the mid- to long-termIndiaNotes.com
 
Fce rashtriya chemicals_07jul15
Fce rashtriya chemicals_07jul15Fce rashtriya chemicals_07jul15
Fce rashtriya chemicals_07jul15IndiaNotes.com
 
Capital First: Q4FY15 net profit up 22.28% y/y to Rs. 364.73 mn; Buy
Capital First: Q4FY15 net profit up 22.28% y/y to Rs. 364.73 mn; BuyCapital First: Q4FY15 net profit up 22.28% y/y to Rs. 364.73 mn; Buy
Capital First: Q4FY15 net profit up 22.28% y/y to Rs. 364.73 mn; BuyIndiaNotes.com
 

Similar to Firstcall gillette 01jun15[1] (20)

GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
Sanofi India: Q2CY14 net rises 12.30%, maintain buy
 Sanofi India: Q2CY14 net rises 12.30%, maintain buy Sanofi India: Q2CY14 net rises 12.30%, maintain buy
Sanofi India: Q2CY14 net rises 12.30%, maintain buy
 
Firstcall atul 7may15[1]
Firstcall atul 7may15[1]Firstcall atul 7may15[1]
Firstcall atul 7may15[1]
 
Divi's Lab Q4FY15: Net profit up 18.57% y/y to INR2,289.10m, Firstcall recomm...
Divi's Lab Q4FY15: Net profit up 18.57% y/y to INR2,289.10m, Firstcall recomm...Divi's Lab Q4FY15: Net profit up 18.57% y/y to INR2,289.10m, Firstcall recomm...
Divi's Lab Q4FY15: Net profit up 18.57% y/y to INR2,289.10m, Firstcall recomm...
 
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyAgro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
 
Cadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India Equity
Cadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India EquityCadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India Equity
Cadila Healthcare: Sales jump 22% during Q4FY14, buy - Firstcall India Equity
 
Firstcall recommends an ethnic Indian foods scrip
Firstcall recommends an ethnic Indian foods scripFirstcall recommends an ethnic Indian foods scrip
Firstcall recommends an ethnic Indian foods scrip
 
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 yearsBuy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
 
Tata Sponge: Q1 Net grows a whopping 145.45%, buy
Tata Sponge: Q1 Net grows a whopping 145.45%, buyTata Sponge: Q1 Net grows a whopping 145.45%, buy
Tata Sponge: Q1 Net grows a whopping 145.45%, buy
 
Firstcall recommend GHCL on 31.45% y/y rise in Q4FY15 net profit
Firstcall recommend GHCL on 31.45% y/y rise in Q4FY15 net profitFirstcall recommend GHCL on 31.45% y/y rise in Q4FY15 net profit
Firstcall recommend GHCL on 31.45% y/y rise in Q4FY15 net profit
 
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buyWelspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
 
Fce tvs motors_28_jul15
Fce tvs motors_28_jul15Fce tvs motors_28_jul15
Fce tvs motors_28_jul15
 
SKF India's net profit jumps to Rs512.40 mn during Q1CY15; Buy
SKF India's net profit jumps to Rs512.40 mn during Q1CY15; BuySKF India's net profit jumps to Rs512.40 mn during Q1CY15; Buy
SKF India's net profit jumps to Rs512.40 mn during Q1CY15; Buy
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 
Firstcall sandesh 10_apr15[1]
Firstcall sandesh 10_apr15[1]Firstcall sandesh 10_apr15[1]
Firstcall sandesh 10_apr15[1]
 
Sun TV can be bought for target of Rs430 for the mid- to long-term according ...
Sun TV can be bought for target of Rs430 for the mid- to long-term according ...Sun TV can be bought for target of Rs430 for the mid- to long-term according ...
Sun TV can be bought for target of Rs430 for the mid- to long-term according ...
 
Go long on Simmonds Marshall for the mid- to long-term
Go long on Simmonds Marshall for the mid- to long-termGo long on Simmonds Marshall for the mid- to long-term
Go long on Simmonds Marshall for the mid- to long-term
 
Fce rashtriya chemicals_07jul15
Fce rashtriya chemicals_07jul15Fce rashtriya chemicals_07jul15
Fce rashtriya chemicals_07jul15
 
Capital First: Q4FY15 net profit up 22.28% y/y to Rs. 364.73 mn; Buy
Capital First: Q4FY15 net profit up 22.28% y/y to Rs. 364.73 mn; BuyCapital First: Q4FY15 net profit up 22.28% y/y to Rs. 364.73 mn; Buy
Capital First: Q4FY15 net profit up 22.28% y/y to Rs. 364.73 mn; Buy
 

More from IndiaNotes.com

Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CAREIndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16EIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyIndiaNotes.com
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15IndiaNotes.com
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndiaNotes.com
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetIndiaNotes.com
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNotes.com
 
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declinesATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declinesIndiaNotes.com
 
Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15IndiaNotes.com
 
Fce sqs india_29_jul15
Fce sqs india_29_jul15Fce sqs india_29_jul15
Fce sqs india_29_jul15IndiaNotes.com
 
Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15IndiaNotes.com
 
Lumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buyLumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buyIndiaNotes.com
 

More from IndiaNotes.com (18)

Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
 
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declinesATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
 
Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15
 
Fce sqs india_29_jul15
Fce sqs india_29_jul15Fce sqs india_29_jul15
Fce sqs india_29_jul15
 
Nb maxwell 29_july15
Nb  maxwell 29_july15Nb  maxwell 29_july15
Nb maxwell 29_july15
 
Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15
 
Lumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buyLumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buy
 

Firstcall gillette 01jun15[1]

  • 1. CMP 4521.90 Target Price 5110.00 ISIN: INE322A01010 May 30th , 2015 GILLETTE INDIA LIMITED Result Update (PARENT BASIS): Q3 FY15 BUYBUYBUYBUY Stock Data Sector FMCG BSE Code 507815 Face Value / Div. Per Share 10.00 52wk. High / Low (Rs.) 4999.00/1925.05 Volume (2wk. Avg ) 890 Market Cap ( Rs in mn ) 147368.72 Annual Estimated Results (A*: Actual / E*: Estimated) Years FY14A FY15E FY16E Net Sales 17497.90 19613.20 21574.52 EBITDA 1140.00 2242.89 2587.63 Net Profit 514.20 1167.40 1370.36 EPS 15.78 35.82 42.05 P/E 286.60 126.24 107.54 Shareholding Pattern (%) 1 Year Comparative Graph GILLETTE INDIA LTD BSE SENSEX Highlights Gillette India Limited offers personal grooming, oral care, and portable power products in India and internationally. The company’s Net Sales was at Rs. 4941.40 million for the Mar quarter of FY15 compared to Rs. 4555.00 million in corresponding quarter of previous year, registered a robust growth of 8.48% y-o-y. In Q3 FY15, PAT or Net Profit grew by 262.74% y-o-y and stood at Rs. 307.60 million compared to Rs. 84.80 million in Q3 FY14. During the March quarter, Profit before interest, depreciation and tax is Rs. 550.70 million as against Rs. 224.30 million in the corresponding period of the previous year. In Q3 FY15, Profit before Tax (PBT) ramps up by 213.43% to Rs. 438.80 million from Rs. 140.00 million in Q3 FY14. For Q3 FY15, Sales in grooming portfolio were up by 9% to Rs. 3555.10 million from Rs. 3247.00 million for the corresponding quarter of previous year. In Q3 FY15, Oral Care and Portable Power business delivered sales growth of 6% & 4% of Rs. 1168.90 million and Rs. 217.40 million respectively compared to prior period of previous year. Net profit grew by 146.11% to Rs. 853.00 million for the end of 9M FY15 from Rs 346.60 million for the end of 9M FY14. Net Sales and PAT of the company are expected to grow at a CAGR of 15% & 16% over 2013 to 2016E respectively. PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%) Gillette India Ltd 4521.90 147368.72 15.78 286.60 22.90 150.00 Colgate Palmolive Ltd 2000.55 272060.40 41.10 48.68 23.48 2400.00 Procter & Gamble Hygiene & Health Care LTD 6366.25 206653.20 101.34 62.82 20.61 275.00 Godrej Consumer Products Ltd 1074.00 365640.00 19.22 55.88 9.94 550.00
  • 2. ANALYSIS & RECOMMENDATION - ‘BUY’ Gillette India Limited reported 8.74% rise in total Income (including other income) in its 3rd quarter March results. Total Income stood at Rs. 5006.40 million compared to Rs. 4603.80 million in corresponding quarter of previous year. Growth in sales was seen across all business segments – Grooming (9%), Oral Care (6%) & Portable Power (4%). The company reported Operating Profit or EBDITA of Rs. 550.70 million in Q3 FY15 compared to Rs. 224.30 million in Q3 FY14. In the same Mar quarter of FY15, Profit after Tax Jumps to 262.74% y-o-y of Rs. 307.60 million compared to Rs. 84.80 million in the same period previous year. Net profit of the company has shown a three digit growth performance behind productivity driven cost .savings and operational excellence. For the nine months ended of FY15, the company registered a growth of 12.80% in Net sales to Rs. 14325.90 million from Rs. 12700.70 million for the nine months ended of FY14. Net profit grew by 146.11% to Rs. 853.00 million for the end of 9M FY15 from Rs 346.60 million for the end of 9M FY14.Gillette, Oral-B & Duracell have strong brand recall & command significant market share in their respective categories. Thus, we recommend ‘BUY’ for ‘Gillette India Ltd’ with a target price of Rs. 5110.00 for medium term investment. QUARTERLY HIGHLIGHTS (PARENT BASIS) Results updates- Q3 FY15, Gillette India Limited Is one of India’s well known FMCG companies that has its portfolio Gillette Mach 3 Torbo, Oral-B and Duracell is a World leading brands. Reported its financial result for the quarter ended 31st Mar, 2015. The company’s Net profit Jumps to Rs. 307.60 million against Rs. 84.80 million in the corresponding quarter of previous year, an increase of 262.74% y-o-y. Net Sales of Rs. 4941.40 million for the March quarter of FY15 compared to Rs. 4555.00 million for the corresponding quarter of previous year. Driven by the company’s focus on innovation, net sales increased a growth of 8.48% y-o-y with a robust growth across all segments including Grooming, Oral Care and portable power. Profit before interest, depreciation and tax is Rs. 550.70 million, an increase of 145.52% y-o-y as against Rs. 224.30 million in the corresponding period of the previous year. For the March quarter, Reported earnings per share of the company stood at Rs. 9.44 a share, registering 262.74% increase over previous year period. Rs. In Mn Mar-15 Mar-14 % Change Net Sales 4941.40 4555.00 8.48 PAT 307.60 84.80 262.74 EPS 9.44 2.60 262.74 EBITDA 550.70 224.30 145.52
  • 3. Break Up of Expenditure (Rs. In Million) Q3 FY15 Q3 FY14 CHNG % Cost of raw & packing materials consumed 1057.50 1097.60 -4% Purchase of stock-in-trade 1022.10 1138.60 -10% Employees Benefit Expenses 312.80 176.40 77% Depreciation and amortization 105.60 79.80 32% Advertising & sales promotion expenses 1167.10 1238.40 -6% Other Expenditure 734.60 763.70 -4% Segment Revenue Rs. In Mn Q3 FY15 Q3 FY14 CHNG % Grooming 3555.10 3247.00 9% Portable power 217.40 208.30 4% Oral Care 1168.90 1099.70 6%
  • 4. COMPANY PROFILE Gillette India Limited offers personal grooming, oral care, and portable power products in India and internationally. It provides personal grooming products, such as blades, razors, and toiletries under the Gillette brand; oral care products, including tooth brushes and other oral care products under the Oral-B brand; and portable power products comprising batteries under the Duracell brand. The company, formerly known as Indian Shaving Products Limited, was incorporated in 1985 and is based in Mumbai, India. Gillette India Limited is a subsidiary of Procter & Gamble India Holdings B.V. P&G entered India in 1988, and now serves over 650 mm consumers across India. The company presence in household, beauty, grooming and health care segments. Acquired Gillette India in 2005 – Fully integrated with P&G’s strategies & values P&G operates two listed entities (Gillette India Limited and Procter & Gamble Hygiene & Health Care Limited) & one wholly owned subsidiary (Procter & Gamble Home Products Limited) in India. Products • Personal grooming- blades & razors • Oral care • Portable power
  • 5. Financial Statements & Estimations (PARENT BASIS) (A*- Actual, E* -Estimations & Rs. In Millions) Balance sheet as at June 30, 2013A- 2016E 2013A 2014A 2015E 2016E EQUITY AND LIABILITIES: Shareholders’ Funds: Share Capital 325.90 325.90 325.90 325.90 Reserves and Surplus 6166.40 6108.70 6719.57 7324.33 1) Sub Total - Net worth 6492.30 6434.60 7045.47 7650.23 Non-Current Liabilities: Deferred Tax Liabilities [Net] 64.00 23.50 10.58 5.82 Other Long Term Liabilities 0.20 0.20 0.20 0.20 Long Term Provisions 15.00 21.60 24.62 27.09 2) Sub Total - Non Current Liabilities 79.20 45.30 35.40 33.10 Current Liabilities: Trade Payables 2236.70 2560.50 2893.37 3182.70 Other Current Liabilities 653.40 515.80 533.34 544.00 Short Term Provisions 928.70 984.40 610.33 384.51 3) Sub Total - Current Liabilities 3818.80 4060.70 4037.03 4111.21 Total Liabilities (1+2+3) 10390.30 10540.60 11117.90 11794.55 ASSETS: Non-Current Assets: Fixed Assets: Tangible Assets 1702.10 1726.30 1771.18 1799.52 Capital work-in-progress 297.80 608.40 797.00 940.46 a) Sub Total - Fixed Assets: 1999.90 2334.70 2568.19 2739.99 b) Long Term Loans and Advances 1014.80 1237.90 1435.96 1608.28 4) Sub Total - Non-Current Assets 3014.70 3572.60 4004.15 4348.27 Current Assets: Inventories 2397.30 2305.50 2503.77 2618.95 Trade Receivables 927.00 922.60 929.98 948.58 Cash and Bank Balances 1668.20 1696.10 908.23 935.48 Short Term Loans and Advances 2183.10 1975.80 2696.97 2862.49 Other Current Assets 200.00 68.00 74.80 80.78 5) Sub Total - Current Assets 7375.60 6968.00 7113.75 7446.28 Total Assets (4+5) 10390.30 10540.60 11117.90 11794.55
  • 6. Annual Profit & Loss Statement for the period of 2013 to 2016E Value(Rs.in.mn) FY13A FY14A FY15E FY16E Description 12m 12m 12m 12m Net Sales 14377.20 17497.90 19613.20 21574.52 Other Income 365.50 316.20 361.40 451.75 Total Income 14742.70 17814.10 19974.60 22026.27 Expenditure -13046.80 -16674.10 -17731.70 -19438.64 Operating Profit 1695.90 1140.00 2242.89 2587.63 Interest -0.20 -3.60 -46.98 -60.13 Gross profit 1695.70 1136.40 2195.92 2527.50 Depreciation -313.20 -329.80 -416.79 -466.80 Profit Before Tax 1382.50 806.60 1779.13 2060.69 Tax -510.90 -292.40 -611.73 -690.33 Net Profit 871.60 514.20 1167.40 1370.36 Equity capital 325.90 325.90 325.90 325.90 Reserves 6166.40 6108.70 6780.66 7324.33 Face value 10.00 10.00 10.00 10.00 EPS 26.74 15.78 35.82 42.05 Quarterly Profit & Loss Statement for the period of 30th Sept 2014 to 30th June, 2015E Value(Rs.in.mn) 30-Sep-14 31-Dec-14 31-Mar-15 30-Jun-15E Description 3m 3m 3m 3m Net Sales 4399.80 4984.70 4941.40 5287.30 Other income 156.60 56.60 65.00 83.20 Total Income 4556.40 5041.30 5006.40 5370.50 Expenditure -4172.90 -4318.10 -4455.70 -4785.00 Operating profit 383.50 723.20 550.70 585.49 Interest -24.00 -13.40 -6.30 -3.28 Gross profit 359.50 709.80 544.40 582.22 Depreciation -85.00 -118.90 -105.60 -107.29 Profit Before Tax 274.50 590.90 438.80 474.93 Tax -97.70 -222.30 -131.20 -160.53 Net Profit 176.80 368.60 307.60 314.40 Equity capital 325.90 325.90 325.90 325.90 Face value 10.00 10.00 10.00 10.00 EPS 5.42 11.31 9.44 9.65
  • 7. Ratio Analysis Particulars FY13A FY14A FY15E FY16E EPS (Rs.) 26.74 15.78 35.82 42.05 EBITDA Margin (%) 11.80% 6.52% 11.44% 11.99% PBT Margin (%) 9.62% 4.61% 9.07% 9.55% PAT Margin (%) 6.06% 2.94% 5.95% 6.35% P/E Ratio (x) 169.08 286.60 126.24 107.54 ROE (%) 13.43% 7.99% 16.57% 17.91% ROCE (%) 30.95% 22.84% 37.75% 39.93% EV/EBITDA (x) 85.91 127.78 65.30 56.59 Book Value (Rs.) 199.21 197.44 216.19 234.74 P/BV 22.70 22.90 20.92 19.26 Charts
  • 8. Outlook and Conclusion At the current market price of Rs.4521.90, the stock P/E ratio is at 126.24 x FY15E and 107.54 x FY16E respectively. Earning per share (EPS) of the company for the earnings for FY15E and FY16E is seen at Rs.35.82 and Rs.42.05 respectively. Net Sales and PAT of the company are expected to grow at a CAGR of 16% & 15% over 2013 to 2016E respectively. On the basis of EV/EBITDA, the stock trades 65.30 x for FY15E and 56.59 x for FY16E. Price to Book Value of the stock is expected to be at 20.92 x and 19.26 x respectively for FY15E and FY16E. We recommend ‘BUY’ in this particular scrip with a target price of Rs.5110.00 for Medium to Long term investment. Industry Overview The Indian FMCG sector is around $15 Billion and continues to grow at a healthy pace, though it has slowed down versus the historical growth rate. The long term prospects remain bright. There is significant opportunity to grow penetration, trial and consumption. Has strong Indian companies and major multinationals operating in this area offering a wide array of products to the Indian consumer. MALE GROOMING — BLADES & RAZOR Blades & Razor sector is a big category and represents a sizable growth opportunity for this Company. The Blades & Razors market size is estimated at over Rs. 20000.00 mn. The strong portfolio and outstanding equity of Gillette has helped us deliver another year of robust double digit growth and record shares. ORAL CARE The Oral Care category which is over Rs.100000.00 mn presents significant opportunities as well as challenges in India. The Oral Care business delivered over 30% topline growth versus last year driven by product innovations including launch of Oral-B toothpaste and focus on brand fundamentals. The Company’s entry into the toothpastemarket is delivering results in line with expectations but will require significant investment. PORTABLE POWER The growing usage in the high and mid drain devices like toys and cameras and increased purchasing power in India indicate a good potential in the coming years for alkaline batteries and thus for Duracell. Sales in this segment were up more than 20% versus last year.
  • 9. Outlook, Risks and Opportunities The Indian economy presents significant opportunity with a growing population, category whitespace and rising incomes. We do expect growth rate in the categories we compete to be around high single digits. However, high inflation, supply bottlenecks and intense competition present significant near term challenges. The Company endeavors to overcome these risks and to sustain and improve its market position behind superior innovation, strategic pricing, effective communication and by focusing relentlessly on productivity. Conclusion While the rural market certainly offers a big attraction to marketers, it would be naïve to think that any company can enter the market without facing any problems and walk away with a sizable share. Distribution is the most important variable in the marketing plans of most consumer goods manufacturers, because managing such a massive sales and distribution network is in itself a huge task. This sector will continue to see growth as it depends on an ever-increasing internal market for consumption, and demand for these goods remains more or less constant, irrespective of recession or inflation. Hence this sector will grow, though it may not be a smooth growth path, due to the present world-wide economic slowdown, rising inflation and fall of the rupee. This sector will see good growth in the long run and hiring will continue to remain robust. The Indian economy is showing positive signals of regaining growth momentum, especially in core areas of Manufacturing and Infrastructure. However, the weaker than expected monsoon is an area of worry and could impact growth as well as consumption. The recent stability in the rupee is welcome news as it enables the economic recovery. Disclaimer: This document is prepared by our research analysts and it does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable but we do not represent that it is accurate or complete and it should not be relied on as such. Firstcall Research or any of its affiliates shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Firstcall Research and/ or its affiliates and/or employees will not be liable for the recipients’ investment decision based on this document.
  • 10. Firstcall India Equity Research: Email – info@firstobjectindia.com C.V.S.L.Kameswari Pharma & Diversified U. Janaki Rao Capital Goods B. Anil Kumar Auto, IT & FMCG M. Vinayak Rao Diversified G. Amarender Diversified Firstcall Research Provides Industry Research on all the Sectors and Equity Research on Major Companies forming part of Listed and Unlisted Segments For Further Details Contact: Tel.: 022-2527 2510/2527 6077 / 25276089 Telefax: 022-25276089 040-20000235 /20000233 E-mail: info@firstobjectindia.com www.firstcallresearch.com